#1 Clinical Trials Search in Europe

Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy Poland Spain

  • Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • Study on Cyclophosphamide for Patients with Advanced Breast Cancer with TP53 Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Norway

  • Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy Poland Slovakia +2

  • Study Comparing Oral Paclitaxel (DHP107) and IV Paclitaxel for Patients with Recurrent or Metastatic HER2 Negative Breast Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Hungary

  • Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Spain

  • Study of fulvestrant and palbociclib combination for postmenopausal women with hormone receptor-positive metastatic breast cancer who completed 5 years of hormone therapy or have new metastatic disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Ireland Spain

  • Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain